{"id":52192,"date":"2025-12-29T20:30:26","date_gmt":"2025-12-29T12:30:26","guid":{"rendered":"https:\/\/flcube.com\/?p=52192"},"modified":"2025-12-29T20:30:27","modified_gmt":"2025-12-29T12:30:27","slug":"bdgene-doses-first-patient-with-bd920-crispr-gene-therapy-for-hpv-16-hsil","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52192","title":{"rendered":"BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL"},"content":{"rendered":"\n<p><strong>Shanghai BDgene Technology Co., Ltd.<\/strong> announced that <strong>BD920<\/strong>, its <strong>in vivo CRISPR gene editing therapy<\/strong>, has commenced <strong>Phase\u202f1 clinical trials<\/strong> and completed <strong>first\u2011patient dosing<\/strong> for the treatment of <strong>cervical high\u2011grade squamous intraepithelial lesions (HSIL)<\/strong> associated with <strong>HPV\u201116 infection<\/strong>, becoming the <strong>world\u2019s first CRISPR\u2011based approach<\/strong> for this indication.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-clinical-milestone\">Regulatory &amp; Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>BD920 (in vivo CRISPR gene editing therapy)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Shanghai BDgene Technology (private)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>HPV\u201116\u2011associated HSIL (cervical high\u2011grade squamous intraepithelial lesions)<\/td><\/tr><tr><td><strong>Study<\/strong><\/td><td>Phase\u202f1 trial (first\u2011patient dosed)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>CRISPR\u2011mediated deletion of HPV\u201116 E6\/7 oncogenes<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Local cervical injection (minimally invasive)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>First\u2011in\u2011world CRISPR therapy<\/strong> for HSIL; potential non\u2011surgical curative option<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-background-amp-unmet-need\">Disease Background &amp; Unmet Need<\/h2>\n\n\n\n<p><strong>HSIL Epidemiology &amp; Burden (China)<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: ~500,000 women diagnosed with HSIL annually; <strong>HPV\u201116<\/strong> accounts for <strong>~55%<\/strong> of cases<\/li>\n\n\n\n<li><strong>Malignant Risk<\/strong>: 20\u201130% progression rate to cervical cancer without intervention<\/li>\n\n\n\n<li><strong>Current Standard of Care<\/strong>: <strong>Surgical excision<\/strong> (LEEP, conization)<\/li>\n\n\n\n<li><strong>Drawbacks<\/strong>: Surgical trauma, post\u2011operative bleeding\/infection (10\u201115% complication rate), inability to eradicate persistent HPV infection, <strong>recurrence rate 15\u201125%<\/strong><\/li>\n\n\n\n<li><strong>Market Gap<\/strong>: No approved <strong>non\u2011surgical disease\u2011modifying therapy<\/strong>; significant demand for fertility\u2011preserving treatment in women of childbearing age<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-bd920-mechanism\">Technology Platform: BD920 Mechanism<\/h2>\n\n\n\n<p><strong>CRISPR In Vivo Gene Editing<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeting<\/strong>: Dual gRNA design precisely locates and deletes <strong>HPV\u201116 E6\/7 viral oncogenes<\/strong> in infected cervical epithelial cells<\/li>\n\n\n\n<li><strong>Effect<\/strong>: Eliminates E6\/7\u2011mediated p53\/Rb pathway suppression \u2192 <strong>induces apoptosis<\/strong> of transformed cells<\/li>\n\n\n\n<li><strong>Delivery<\/strong>: <strong>AAV\u2011CRISPR<\/strong> vector optimized for cervical tissue transduction; local injection avoids systemic exposure<\/li>\n\n\n\n<li><strong>Durability<\/strong>: Preclinical data suggests <strong>single administration<\/strong> achieves durable viral clearance and lesion regression<\/li>\n<\/ul>\n\n\n\n<p><strong>Differentiation<\/strong>: Unlike therapeutic vaccines or immunomodulators, BD920 <strong>directly eradicates the viral oncogenic driver<\/strong>, offering potential <strong>curative intent<\/strong> without tissue destruction.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-plan\">Clinical Development Plan<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Design<\/th><th>Primary Endpoints<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase\u202f1<\/strong> (Ongoing)<\/td><td>Open\u2011label, dose\u2011escalation (n=18)<\/td><td>Safety, HPV\u201116 clearance, lesion regression<\/td><td>Topline Q4\u202f2026<\/td><\/tr><tr><td><strong>Phase\u202f2<\/strong> (Planned)<\/td><td>Randomized vs. active comparator (surgery)<\/td><td>Efficacy, non\u2011inferiority, fertility preservation<\/td><td>Initiate H2\u202f2027<\/td><\/tr><tr><td><strong>Phase\u202f3<\/strong><\/td><td>Confirmatory trial for NDA<\/td><td>pCR rate, 2\u2011year recurrence\u2011free survival<\/td><td>2028\u20112030<\/td><\/tr><tr><td><strong>NDA Filing<\/strong><\/td><td>Rolling submission<\/td><td>\u2013<\/td><td>Target <strong>2029<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Efficacy Metrics<\/strong>: Preclinical models showed <strong>&gt;90% HPV\u201116 DNA clearance<\/strong> and <strong>complete lesion regression<\/strong> in 80% of animals within 12 weeks.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-financial-outlook\">Market Opportunity &amp; Financial Outlook<\/h2>\n\n\n\n<p><strong>China HSIL Addressable Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Annual Incident Cases<\/strong>: ~500,000<\/li>\n\n\n\n<li><strong>HPV\u201116 Positive Subset<\/strong>: ~275,000<\/li>\n\n\n\n<li><strong>Target Population<\/strong>: Women seeking <strong>fertility\u2011sparing<\/strong> or <strong>non\u2011surgical<\/strong> options (estimated 30\u201140% of diagnosed cases)<\/li>\n\n\n\n<li><strong>Pricing<\/strong>: Projected <strong>\u00a5120,000\u2011150,000<\/strong> per treatment course (positioned between surgery costs and biologics)<\/li>\n\n\n\n<li><strong>Peak Penetration<\/strong>: <strong>15\u201120%<\/strong> by 2032<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Revenue Forecast<\/th><th>2028E<\/th><th>2030E<\/th><th>2032E<\/th><\/tr><\/thead><tbody><tr><td><strong>Treatable patients<\/strong><\/td><td>80,000<\/td><td>120,000<\/td><td>150,000<\/td><\/tr><tr><td><strong>Market share<\/strong><\/td><td>2%<\/td><td>8%<\/td><td>15%<\/td><\/tr><tr><td><strong>Annual sales<\/strong><\/td><td>\u00a5240\u202fmillion<\/td><td>\u00a51.44\u202fbillion<\/td><td>\u00a52.7\u202fbillion<\/td><\/tr><tr><td><strong>(US$ equivalent)<\/strong><\/td><td>(~$34\u202fM)<\/td><td>(~$200\u202fM)<\/td><td>(~$380\u202fM)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapy<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Key Limitation<\/th><\/tr><\/thead><tbody><tr><td><strong>BD920<\/strong><\/td><td><strong>BDgene<\/strong><\/td><td>CRISPR gene editing (HPV\u201116 E6\/7 deletion)<\/td><td>Phase\u202f1<\/td><td>First\u2011in\u2011class; safety TBD<\/td><\/tr><tr><td><strong>VGX\u20113100<\/strong><\/td><td>Inovio<\/td><td>DNA vaccine (HPV E6\/7 immunotherapy)<\/td><td>Phase\u202f3 (US)<\/td><td>Modest efficacy (~50% response)<\/td><\/tr><tr><td><strong>Papilocare<\/strong><\/td><td>Ionis<\/td><td>TLR agonist (immune modulation)<\/td><td>Phase\u202f2<\/td><td>Non\u2011curative; requires repeated dosing<\/td><\/tr><tr><td><strong>Surgery (LEEP)<\/strong><\/td><td>Standard of care<\/td><td>Tissue excision<\/td><td>Marketed<\/td><td>Invasive; fertility impact; recurrence<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Moat<\/strong>: <strong>8 issued patents<\/strong> covering CRISPR gRNA design, AAV delivery vector, and cervical administration method provide <strong>protected market entry<\/strong> through 2040.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-strategy-amp-advantages\">Regulatory Strategy &amp; Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Breakthrough Therapy Designation<\/strong>: BD920 qualifies for NMPA\u2019s <strong>priority review<\/strong> and <strong>conditional approval<\/strong> pathway based on unmet need<\/li>\n\n\n\n<li><strong>Orphan\u2011Like Incentive<\/strong>: While not rare disease, <strong>first\u2011in\u2011world status<\/strong> may enable <strong>rolling review<\/strong> and <strong>real\u2011world evidence (RWE)<\/strong> acceptance<\/li>\n\n\n\n<li><strong>International Expansion<\/strong>: Planned <strong>FDA IND<\/strong> filing in <strong>2027<\/strong> leveraging China data; HPV\u201116 prevalence similar in US\/EU<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief includes forward\u2011looking statements regarding BD920\u2019s clinical development trajectory, regulatory pathway, market penetration, and revenue forecasts. Actual results may differ materially due to clinical safety\/efficacy outcomes, competitive responses, and NMPA\/FDA regulatory decisions..<a href=\"https:\/\/flcube.com\/\"><\/a><a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai BDgene Technology Co., Ltd. announced that BD920, its in vivo CRISPR gene editing therapy,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52193,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1398,62,111,66],"class_list":["post-52192","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bdgene-technology","tag-clinical-trial-approval-initiation","tag-crispr","tag-gene-therapy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai BDgene Technology Co., Ltd. announced that BD920, its in vivo CRISPR gene editing therapy, has commenced Phase\u202f1 clinical trials and completed first\u2011patient dosing for the treatment of cervical high\u2011grade squamous intraepithelial lesions (HSIL) associated with HPV\u201116 infection, becoming the world\u2019s first CRISPR\u2011based approach for this indication.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52192\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL\" \/>\n<meta property=\"og:description\" content=\"Shanghai BDgene Technology Co., Ltd. announced that BD920, its in vivo CRISPR gene editing therapy, has commenced Phase\u202f1 clinical trials and completed first\u2011patient dosing for the treatment of cervical high\u2011grade squamous intraepithelial lesions (HSIL) associated with HPV\u201116 infection, becoming the world\u2019s first CRISPR\u2011based approach for this indication.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52192\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-29T12:30:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-29T12:30:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2903-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52192#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52192\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL\",\"datePublished\":\"2025-12-29T12:30:26+00:00\",\"dateModified\":\"2025-12-29T12:30:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52192\"},\"wordCount\":600,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52192#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2903-1.webp\",\"keywords\":[\"BDgene Technology\",\"Clinical trial approval \\\/ initiation\",\"CRISPR\",\"Gene therapy\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52192#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52192\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52192\",\"name\":\"BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52192#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52192#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2903-1.webp\",\"datePublished\":\"2025-12-29T12:30:26+00:00\",\"dateModified\":\"2025-12-29T12:30:27+00:00\",\"description\":\"Shanghai BDgene Technology Co., Ltd. announced that BD920, its in vivo CRISPR gene editing therapy, has commenced Phase\u202f1 clinical trials and completed first\u2011patient dosing for the treatment of cervical high\u2011grade squamous intraepithelial lesions (HSIL) associated with HPV\u201116 infection, becoming the world\u2019s first CRISPR\u2011based approach for this indication.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52192#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52192\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52192#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2903-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2903-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52192#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai BDgene Technology Co., Ltd. announced that BD920, its in vivo CRISPR gene editing therapy, has commenced Phase\u202f1 clinical trials and completed first\u2011patient dosing for the treatment of cervical high\u2011grade squamous intraepithelial lesions (HSIL) associated with HPV\u201116 infection, becoming the world\u2019s first CRISPR\u2011based approach for this indication.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52192","og_locale":"en_US","og_type":"article","og_title":"BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL","og_description":"Shanghai BDgene Technology Co., Ltd. announced that BD920, its in vivo CRISPR gene editing therapy, has commenced Phase\u202f1 clinical trials and completed first\u2011patient dosing for the treatment of cervical high\u2011grade squamous intraepithelial lesions (HSIL) associated with HPV\u201116 infection, becoming the world\u2019s first CRISPR\u2011based approach for this indication.","og_url":"https:\/\/flcube.com\/?p=52192","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-29T12:30:26+00:00","article_modified_time":"2025-12-29T12:30:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2903-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52192#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52192"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL","datePublished":"2025-12-29T12:30:26+00:00","dateModified":"2025-12-29T12:30:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52192"},"wordCount":600,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52192#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2903-1.webp","keywords":["BDgene Technology","Clinical trial approval \/ initiation","CRISPR","Gene therapy"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52192#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52192","url":"https:\/\/flcube.com\/?p=52192","name":"BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52192#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52192#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2903-1.webp","datePublished":"2025-12-29T12:30:26+00:00","dateModified":"2025-12-29T12:30:27+00:00","description":"Shanghai BDgene Technology Co., Ltd. announced that BD920, its in vivo CRISPR gene editing therapy, has commenced Phase\u202f1 clinical trials and completed first\u2011patient dosing for the treatment of cervical high\u2011grade squamous intraepithelial lesions (HSIL) associated with HPV\u201116 infection, becoming the world\u2019s first CRISPR\u2011based approach for this indication.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52192#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52192"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52192#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2903-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2903-1.webp","width":1080,"height":608,"caption":"BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52192#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2903-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52192"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52192\/revisions"}],"predecessor-version":[{"id":52194,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52192\/revisions\/52194"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52193"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}